Мақола

An international survey of classification and treatment choices for group D retinoblastoma

Christina ScelfoOphthalmic Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York 10065, USAJasmine H. FrancisDepartment of Ophthalmology, Weill-Cornell Medical Center, New York 10065, USAVikas KhetanDepartment of Vitreoretinal and Ocular Oncology, Sankara Nathralaya, Chennai 600066, IndiaThomas M. JenkinsOcular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Pennsylvania 19107, USABrian P. MarrDepartment of Ophthalmology, Weill-Cornell Medical Center, New York 10065, USADavid H. AbramsonDepartment of Ophthalmology, Weill-Cornell Medical Center, New York 10065, USACarol L. ShieldsOcular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Pennsylvania 19107, USAJacob Pe’erHadassah - Hebrew University Medical Center, Jerusalem 91120, IsraelFrancis L. MunierJules-Gonin Eye Hospital, Lausanne 1004, SwitzerlandJesse L. BerryUSC Roski Eye Institute, Children's Hospital of Los Angeles, California 90033, USAJ. William HarbourOcular Oncology Service, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Florida 33136, USAА.А. YarovoyOcular Oncology Department, S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow 127486, RussiaEvandro LucenaDepartment of Ocular Oncology, Instituto Nacional de Cancer, Rio de Janeiro 1122, BrazilTimothy G. MurrayMurray Ocular Oncology and Retina, Miami Children's Hospital, Florida 33143, USAPooja BhagiaSt. Joseph's Children's Hospital, New Jersey 07504, USAEvelyn A. PaysseDepartment of Ophthalmology, Baylor College of Medicine, Texas 77030, USASamuray TuncerDepartment of Ophthalmology, Ocular Oncology, Istanbul Medical Faculty, Istanbul University, Istanbul 34452, TurkeyGuillermo ChantadaOncology Department, Hospital JP Garrahan, Buenos Aires 1245, ArgentinaAnnette C. MollDepartment of Ophthalmology, VU University Medical Center, Amsterdam 1081, the NetherlandsTatiana L. UshakovaDepartment of Head and Neck Tumors, Science Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Center, Moscow 115478, RussiaDavid A. PlagerPediatric Ophthalmology and Adult Strabismus, Riley Hospital for Children, Indiana University Medical Center, Indiana 46202, USAIslamov ZiyovuddinNational Oncology Center of Uzbekistan, Tashkent 110508, UzbekistanCarlos A. LealInstituto Nacional de Pediatria, Coyoacan 04530, MexicoMiguel A. MaterinDepartment of Ophthalmology and Visual Science, Smilow Cancer Hospital at Yale New Haven, CT 06520, USAXun-Da JiXin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, ChinaJosé Wilson CursinoDepartment of Ophthalmology, Santa Casa Misericordia S. Paulo, Sao Paulo 01221-020, BrazilRodrigo A. PolaniaFundacion Clinica Valle del Lili, Cali, ColumbiaHayyam KıratlıOcular Oncology Service, Hacettepe University School of Medicine, Ankara 06100, TurkeyCharlotta All‐EricssonOcular Oncology Service, St. Erik Eye Hospital, Stockholm 11282, SwedenRejin KebudiIstanbul University, Cerrahpasa Medical Faculty & Oncology Institute, Istanbul 34303, TurkeySantosh G HonavarOphthalmic and Facial Plastic Surgery and Ocular Oncology, Centre for Sight Eye Hospital, Hyderabad 500034, IndiaVicktoria Vishnevskia‐DaiThe Ocular Oncology and Autoimmune Center, Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer 52621, IsraelSidnel EpelmanSanta Marcelina Hospital, Sao Paulo 08452-590, BrazilAnthony B. DanielsDepartment of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, Tennessee 37232, USAJeanie D. LingDepartment of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, Tennessee 37232, USAFousseyni TraoréHospital Gabriel Toure, Bamako, MaliMarco A. Ramírez‐OrtizOphthalmology Service, Hospital Infantil de Mexico Federico Gomez, Mexico City 01020, Mexico

International Journal of Ophthalmologyjournal2017en

ABI

Аннотация

AIM: To determine which IIRC scheme was used by retinoblastoma centers worldwide and the percentage of D eyes treated primarily with enucleation versus globe salvaging therapies as well as to correlate trends in treatment choice to IIRC version used and geographic region. METHODS: An anonymized electronic survey was offered to 115 physicians at 39 retinoblastoma centers worldwide asking about IIRC classification schemes and treatment patterns used between 2008 and 2012. Participants were asked to record which version of the IIRC was used for classification, how many group D eyes were diagnosed, and how many eyes were treated with enucleation versus globe salvaging therapies. Averages of eyes per treatment modality were calculated and stratified by both IIRC version and geographic region. Statistical significance was determined by Chi-square, ANOVA and Kruskal-Wallis tests using Prism. RESULTS: The survey was completed by 29% of physicians invited to participate. Totally 1807 D eyes were diagnosed. Regarding IIRC system, 27% of centers used the Children’s Hospital of Los Angeles (CHLA) version, 33% used the Children’s Oncology Group (COG) version, 23% used the Philadelphia version, and 17% were unsure. The rate for primary enucleation varied between 0 and 100% and the mean was 29%. By IIRC version, primary enucleation rates were: Philadelphia, 8%; COG, 34%; and CHLA, 37%. By geographic region, primary enucleation rates were: Latin America, 57%; Asia, 40%; Europe, 36%; Africa, 10%, US, 8%; and Middle East, 8%. However, systemic chemoreduction was used more often than enucleation in all regions except Latin America with a mean of 57% per center (P<0.0001). CONCLUSION: Worldwide there is no consensus on which IIRC version is used, systemic chemoreduction was the most frequently used initial treatment during the study period followed by enucleation and primary treatment modality, especially enucleation, varied greatly with regards to IIRC version used and geographic region.

Ҳали таржима қилинмаган

Мавзулар

Ocular Oncology and Treatments Ocular Disorders and Treatments Retinal and Macular Surgery

Идентификаторлар

DOI: 10.18240/ijo.2017.06.20

Иқтибослар ва манбалар

0 та иқтибос34 та фойдаланилган манба

Кўрсаткичлар — AkademScholar